Dr. Zelenetz on Anticipated Research in MCL
The combination of BGB-3111 and obinutuzumab for follicular lymphoma: promising preliminary results
Constantine Tam, MBBS, MD, FRACP, FRCPA from the University of Melbourne, Melbourne, Australia discusses the safety and activity of the BTK inhibitor BGB-3111 plus obinutuzumab in follicular lymphoma and chronic lymphocytic leukemia (CLL) patients (NCT02569476). Prof. Tam explains that BGB-3111 is more specific than ibrutinib. When ibrutinib is combined with an antibody, results are often not as good as expected while BGB-3111 has little off-target selectivity. The Phase Ib study evaluates the combination of BGB-3111 and obinutuzumab and has shown that this combination is well-tolerated. Preliminary results are promising with response rates of approximately 70% and a high complete remission rate (CRR) in follicular lymphoma patients suggesting that this may be one of the most active combinations available for relapsed follicular lymphoma.
Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland.